Thursday, October 9th
Hall A Hall B
08:45-09:00 Welcome Coffee
09:00-11:10 IACH 1: Transplant Workshop
Moderators: Mohamad Mohty, France; Arnon Nagler, Israel
09:00-09:30 Tailoring the intensity of conditioning: Didier Blaise, France
09:30-10:00 Long-term complications of allo-HSCT: Bipin Savani, USA
10:00-10:15 Coffee Break
10:15-10:45 VOD after HSCT: 15 years of progress: Mohamad Mohty, France
10:45-10:50 Real-life clinical case presentation: Maria Chiara Auriemma, Italy
10:50-11:10 Panel discussion: All workshop faculty & Zinaida Perić, Croatia, Finn Petersen, Denmark and Hélène Schoemans, Belgium
11:10-11:20 Technical Break
11:20-12:00 IACH 2: Special Session – Next-generation delivery of hematology drugs: the example of an anti-CD38 antibody 11:30-12:00 Advances and Challenges in Essential Thrombocythemia Industry-supported “Meet the Expert” Session
Moderators: Mohamad Mohty, France; Bipin Savani, USA
11:20-11:25 Introduction: Mohamad Mohty, France
11:25-11:40 The OBI system: results from the IRAKLIA and ISASOCUT trials: Arthur Bobin, France
11:40-11:50 Live demonstration of the OBI system
11:50-12:00 Panel discussion: All session faculty & Pascal Avart, France; Claire Copin, France and Emilie Poupardin, France
12:00-12:30 Lunch Break
12:30-13:00 IACH 3: Awards Session
Chairs: Mohamad Mohty, France; Arnon Nagler, Israel
Presentation of the H.J. Khoury Excellence in Research Award
Presentation of the Christian Cailliot Clinical Research Award
Presentation of the Rainer Storb Lifetime Achievement Award with an introduction by Dr Rainer Storb
13:00-14:30 Transplant 1: HLA and donor selection 13:00-14:30 MPNCo&D 1: Essential Thrombocytosis in 2025: Updates and New Directions
Moderators: Florent Malard, France; Frederic Baron, France Moderators: Claire Harrison, UK; Naveen Pemmaraju, USA
13:00-13:20 Graft composition and impact on transplantation platforms: Jurgen Kuball, Netherlands 13:00-13:10 Opening Remarks by the MPNCo&D co-Chairs
13:20-13:40 Stem cell rejuvenation for better transplants: Guy Sauvageau, Canada 13:10-13:25 Future directions and clinical trial approaches in ET: Claire Harrison, UK
13:40-14:00 HLA in transplantation: from structure to function: Roberto Crocchiolo, Italy 13:25-13:40 Management of patients with ET in 2025 – state-of-the-art for standard of care: Anna Godfrey, UK
14:00-14:20 Algorithm for donor selection: Mohamad Mohty, France 13:40-13:55 CALR – Role in pathogenesis and treatment target? Shannon Elf, USA
14:20-14:30 Panel discussion: All session faculty 13:55:-14:10 AI and spatial modeling in MPNs: current and future directions: Daniel Royston, UK
14:10-14:30 Panel discussion: All session faculty
14:30-16:00 Transplant 2: Graft-versus-Host disease 14:30-16:00 MPNCo&D 2: Pre-Fibrotic MF and Myelofibrosis
Moderators: Federico Simonetta, Switzerland; Bipin Savani, USA Moderator: Claire Harrison, UK; Francesco Passamonti, Italy
14:30-14:50 PTCy tolerance and long-term effect: Annalisa Ruggeri, Italy 14:30-14:45 A review of pre-fibrotic MF: updates in 2025: Florian Heidel, Germany
14:50-15:10 T cell depletion or no T cell depletion? Moniek de Witte, Netherlands 14:45-15:00 State-of-the-art treatment of MF – standard of care options: focus on available JAK inhibitors: Ruben Mesa, USA
15:10-15:30 Immune monitoring after allo-HCT: Simona Pagliuca, France 15:00-15:15 Anemia in MF – management and treatment options: current and future: Francesco Passamonti, Italy
15:30-15:50 New treatment for a and cGVHD: Florent Malard, France 15:15-15:30 Novel therapies and future clinical approaches for MF: John Mascarenhas, USA
15:50-16:00 Panel discussion: All session faculty 15:30-16:00 Panel discussion: All session faculty
16:00-16:15 Coffee Break
16:15-17:45 COLYM 1: General Session 16:15-17:45 MPNCo&D 3: Polycythemia Vera and CHIP/Inflammation in MPNs
Moderators: Stefano Luminari, Italy; Anna Sureda, Spain Moderators: Mary Frances McMullin, UK; Adam Mead, UK
16:15-16:20 Case report: Diagnostic complexity and interdisciplinary management of high-grade-B-cell lymphoma with MYC rearrangement in an HIV-positive patient: Chidiebube Ugwu, USA 16:15-16:30 PV in 2025: state-of-the-art and standard of care: Adam Mead, UK
16:20-16:30 Discussion
16:30-16:50 Using molecular studies in lymphoma diagnosis: Alexandra Harrington, USA 16:30-16:45 Novel therapies in PV – clinical trials: Susanne Isfort, Germany
16:50-17:10 Innovation in the prognostic assessment of lymphoma patients: Naren Epperla, USA 16:45-17:00 Reflections on molecular discoveries in erythrocytosis: Mary Frances McMullin, UK
17:10-17:30 Infections and lymphomas: lessons for the clinicians: Luca Arcaini, Italy 17:00-17:15 Inflammation states in MPN – lessons from MDS: Shahram Kordasti, UK
17:30-17:45 Panel discussion: All session faculty 17:15-17:45 Panel discussion: All session faculty
17:45-19:15 COLYM 2: Indolent Lymphomas 17:45-19:00 IACH 4: Progress in the management of chronic GVHD
Moderators: Stefano Luminari, Italy; Jessica Okosun, UK Moderators: Bipin Savani, USA; Mohamad Mohty, France
17:45-17:50 Case report: Unmasking the unexpected: diagnostic complexity and atypical disease progression in a follicular lymphoma case: Adela-Sara Ionescu, Romania 17:45-18:15 Update on the biology of chronic GVHD: Ernst Holler, Germany
17:50-18:00 Discussion 18:15-18:25 Chronic GVHD case presentation 1: Maria Helena Parrinello, Italy
18:00-18:20 Transformation in indolent lymphomas: identification, prediction and management: Jessica Okosun, UK 18:25-18:35 Chronic GVHD case presentation 2: Iman Abou Dalle, Lebanon
18:20-18:40 Follicular lymphomas: impact of novel therapies on the treatment algorithm: Julio Chavez, USA 18:35-19:00 Real-life clinical cases discussion: All session faculty & Hildegard Greinix, Austria, Florent Malard, France and Arnon Nagler, Israel
18:40-19:00 Marginal zone lymphomas: current and future approaches to advanced-stage patients: Côme Bommier, France
19:00-19:15 Panel discussion: All session faculty

IACH track

COMydAL track

COLYM track

MPNCo&D track

Transplant track

Friday, October 10th
Hall A Hall B
08:15-09:45 Transplant 3: ALL management 08:15-09:45 MPNCo&D 4: Immunotherapy, SCT, Novel Approaches in MPNs
Moderators: Annalisa Ruggeri, Italy; Christoph Schmid, Germany Moderators: Anna Godfrey, UK; Susanne Isfort, Germany
08:15-08:35 Does the addition of Blinatumomab change the role of allo-HCT in first line ALL treatment? Sebastian Giebel, Poland 08:15-08:30 Novel clinical approaches targeting CALR – translational/clinical approaches: Bethan Psaila, UK
08:35-08:55 Does remission after CAR T treatment replace allo SCT? Eolia Brissot, France 08:30-09:00 Should blastic phase MPN be aggressively treated? Yes: Tania Jain, USA No: Bart Scott, USA
08:55-09:15 CAR T cell in T-ALL: Nicola Maciocia, UK 09:00-09:15 Recent data to achieve the best from allografting in MF: Donal McLornan, UK
09:15-09:35 The place of CART in B-cell malignancies: Ibrahim Yakoub-Agha, France 09:15-09:45 Panel discussion: All session faculty
09:35-09:45 Panel discussion: All session faculty
09:45-10:00 Coffee Break
10:00-11:30 The Significance of Cytopenias in Myelofibrosis: Optimising Outcomes Through Individualised Care CME Morning Symposium
11:30-11:40 Technical Break
11:40-13:10 Transplant 4: AML management 11:40-13:10 MPNCo&D 5: Spotlight on Rare MPNs: Not as Rare as You Think
Moderators: Zinaida Perić, Croatia; Didier Blaise, France Moderators: Deepti Radia, UK; Andreas Reiter, Germany
11:40-12:00 Predictive score for AML: Alexandros Spyridonidis, Greece 11:40-11:55 CMML – updates and future directions: Daniel Wiseman, UK
12:00-12:20 Conditioning regimen in AML: Raynier Devillier, France 11:55-12:10 Hypereosinophilic syndromes in 2025: Andreas Reiter, Germany
12:20-12:40 Maintenance in AML: Ali Bazarbachi, Lebanon 12:10-12:25 Systemic mastocytosis: Deepti Radia, UK
12:40-13:00 CAR T and TCR construct for AML: Fabio Ciceri, Italy 12:25-12:40 Focus on rare hematologic malignancies: pearls and reflections: Naveen Pemmaraju, USA
13:00-13:10 Panel discussion: All session faculty 12:40-13:10 Panel discussion: All session faculty
13:10-13:40 Lunch Break
13:40-15:10 Optimizing Care in Relapsed Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Practical Approaches to Challenging Decisions Industry-supported Lunch Symposium
15:10-15:20 Technical Break
15:20-16:50 COLYM 3: Chronic Lymphocytic Leukemia 15:20-16:50 COMydAL 1: MDS I
Moderators: Mohamed Kharfan-Dabaja, USA; Stefano Luminari, Italy Moderators: Lionel Adès, France; Astrid Olsnes, Norway
15:20-15:25 Opening Remarks by the COMydAL co-Chairs
15:20-15:40 SPECIAL LECTURE Management of relapsed refractory large B cell lymphoma in countries with no access to CAR T-cell therapy: Ali Bazarbachi, Lebanon 15:25-15:40 An update on IDH inhibitors in MDS: Lionel Adès, France
15:40-15:45 Case report: A case of refractory Richter’s syndrome: Mohamad Hadi El Charif, Lebanon
15:45-15:55 Discussion 15:40-15:55 An update on AZA-based combinations in MDS: Astrid Olsnes, Norway
15:55-16:15 Time-limited vs continuous therapy as front-line treatment of CLL: matching the best approach to the right patient: Talha Munir, UK 15:55-16:10 An update on immune biomarkers and targeting in MDS: Shahram Kordasti, UK
16:15-16:35 Treatment of relapsed and/or refractory CLL after failure of a covalent BTK and BCL2 inhibitors: Farrukh Awan, USA 16:10-16:25 An update on response and MRD assessment in MDS: Arjan van Loosdrecht, Netherlands
16:35-16:50 Panel discussion: All session faculty 16:25-16:50 Panel discussion: All session faculty
16:50-17:00 Coffee Break
17:00-18:30 COLYM 4: Hodgkin Lymphoma 17:00-18:30 COMydAL 2: AML I
Moderators: Andrew Evens, USA; Anna Sureda, Spain Moderators: Uma Borate, USA; Amer Zeidan, USA
17:00-17:05 Case report: A challenging case report of primary refractory Hodgkin lymphoma: a response to anti-PD-1 plus chemotherapy: Merve Yüksel, Turkey 17:00-17:15 Therapeutic implications of clonal evolution in AML and MDS: Simona Pagliuca, France
17:05-17:15 Discussion
17:15-17:35 Divide across the pond: how to select between N-AVD or BrECADD in newly diagnosed cHL? Justin Ferdinandus, Germany 17:15-17:30 AZA-VEN vs AZA-IVO for frontline therapy of older IDH1 mutated AML? Ume Borate, USA
17:35-17:55 Harnessing predictive modelling for individualized therapy in Hodgkin Lymphoma: Andrew Evens, USA 17:30-17:45 How should we stratify AML in 2025: Thomas Cluzeau, France
17:55-18:15 Do all relapsed cHL need an autologous treatment as consolidation? Christine Mauz-Körholz, Germany 17:45-18:00 An update on menin inhibitors in AML patients: Amer Zeidan, USA
18:15-18:30 Panel discussion: All session faculty 18:00-18:30 Panel discussion: All session faculty
Saturday, October 11th
Hall A Hall B
08:15-09:45 Transplant 5: Management of relapse of AML and ALL after allo-HCT 08:15-09:45 COMydAL 3: MDS/MPN
Moderators: Jurgen Kuball, Netherlands; Fabio Ciceri, Italy Moderators: Laura Palomo, Spain; Lisa Pleyer, Austria
08:15-08:35 Biology of leukemia relapse: Giorgio Orofino, Italy 08:15-08:30 Defining MDS/MPN entities for clinical decision making: Daniel Wiseman, UK
08:35-08:55 Clinical case nurses, presented by Annalisa Ruggeri, Italy & Ruth Clout, UK 08:30-08:45 Molecular classification along the myeloid neoplasm spectrum: Matteo Della Porta, Italy
08:55-09:15 Treatment of relapse: Christoph Schmid, Germany 08:45-09:00 CMML molecular landscape: Laura Palomo, Spain
09:15-09:35 Application of DLI: Nicole Santoro, Italy 09:00-09:15 MDS/MPN – an update on therapeutics: Francesco Onida, Italy
09:35-09:45 Panel discussion: All session faculty 09:15-09:45 Panel discussion: All session faculty
09:45-10:00 Coffee Break
10:00-11:30 COLYM 5: Aggressive B-Cell Lymphoma 10:00-11:30 COMydAL 4: MDS II
Moderators: Anna Sureda, Spain; Mohamed Kharfan-Dabaja, USA Moderators: Sophie Park, France; Valeria Santini, Italy
10:00-10:05 Case report: What’s next for R/R DLBCL? A case report of comprehensive NHS-based therapy in a fit patient: Katie Stark, UK 10:00-10:15 Dissecting biology of MDS Del5q: Julia Montoro, Spain
10:05-10:15 Discussion
10:15-10:35 “All comers” vs “molecularly driven” treatment strategies in first-line DLBCL patients: where are we heading to? Umberto Vitolo, Italy 10:15-10:30 Should we improve selection of patients for ESA therapy? Marco Raddi, Italy
10:35-10:55 Changing the field in R/R DLBCL: CAR-T cells and BiEsp MoAb: Carmelo Carlo-Stella, Italy 10:30-10:45 Autoimmunity in MDS: Lin Pierre Zhao, France
10:55-11:15 Is there life after CAR-T? Mechanisms of resistance and potential therapeutic strategies: Roni Shouval, USA 10:45-11:00 Evolving therapeutic algorithm for LR MDS: ESA, luspatercept, imetelstat: Valeria Santini, Italy
11:15-11:30 Panel discussion: All session faculty 11:00-11:30 Panel discussion: All session faculty
11:30-13:00 COLYM 6: Mantle Cell Lymphoma 11:30-13:00 COMydAL 5: AML II
Moderators: Marco Ladetto, Italy; Anna Sureda, Spain Moderators: Valeria Santini, Italy; Amer Zeidan, USA
11:30-11:35 Case report: Peripheral blood blasts in a young patient: Sara Vaz da Silva, Portugal 11:30-11:45 Are retinoids out of fasion in non-APL AML/HR-MDS? Amy DeZern, USA
11:35-11:45 Discussion
11:45-12:05 Should we abandon auto-HCT as first-line consolidation therapy in de novo MCL patients? Olivier Hermine, France 11:45-12:00 An update on TP53 AML biology and targeting in AML/HR-MDS: Max Stahl, Germany
12:05-12:25 Choosing between a BTK inhibitor and CAR-T cell therapy in R/R MCL: Marco Ladetto, Italy 12:00-12:15 Germline predisposition in AML and MDS: Marie Sebert, France
12:25-12:45 Management of relapsed TP53 mutated mantle cell lymphoma: is allogeneic HCT still a major player? Nora Liebers, Germany 12:15-12:30 The role of inflammation in AML and MDS: Antonio Curti, Italy
12:45-13:00 Panel discussion: All session faculty 12:30-13:00 Panel discussion: All session faculty
13:00-13:30 Lunch Break
13:30-15:00 IACH 5: Immunotherapy with bispecifics in myeloma: from A-Z
Moderators: Thierry Facon, France; Mohamad Mohty, France
13:30-13:50 Bispecific antibodies in myeloma: mechanism of action and development: Ludovic Martinet, France
13:50-14:10 Clinical data in the relapsed/refractory setting and toxicity management: Xavier Leleu, France
14:10-14:30 Clinical data in the early disease setting: Cyrille Touzeau, France
14:30-15:00 Expert panel and real-life clinical cases review: All session faculty & Florent Malard, France; Shelisa Radjabaly, Franceaaa
Post-evaluation form
15:00-16:30 IACH 6: Latest advances in hematology
Moderators: Jean El-Cheikh, Lebanon; Mohamad Mohty, France
15:00-15:30 Next generation CAR-T cells: He Huang, China
15:30-16:00 Academy CAR-T cell experience: Arnon Nagler, Israel
16:00-16:30 MRD in multiple myeloma: where do we stand? Mohamad Mohty, France
16:30 Closing Remarks